The FDA established a “green list” import alert covering GLP-1 active pharmaceutical ingredients, intended to stop unverified foreign-sourced APIs from entering the US market. Ingredients from facilities the agency has inspected or evaluated, and which appear to meet its manufacturing standards, are listed; APIs from any other source become subject to detention without physical examination. The agency framed the action around patients using compounded GLP-1s, which are not FDA-approved.
Sources: FDA news release, 5 September 2025
